Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | EVP, CS&PO & Pres. LRL | February 09, 2026 | February 11, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | June 16, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,071.725 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 15,547.862 · Balance 160,071.725 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 72,359 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 72,359 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 547 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 547 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse's SLAT | 2,710 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,710 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
ILLUMINA, INC.
Report date June 16, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,674 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 1,674 · Balance 1,674 F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date June 23, 2026 · Filed June 23, 2026
Section 16 reporting ended · disclosed 2026-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 195,507 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 195,507 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 23, 2026 22:01 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,674 | $164.28 | $275,004.72 |
DisclosureSEC source: 0001110803-26-000142 · form4.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,674 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:25 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 59,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041258 · wk-form4_1780691148.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,507 F1 · shares: Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:24 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 15,547.862 | $1,044.67 | $16,242,385.00 |
DisclosureSEC source: 0001741474-26-000004 · wk-form4_1770845058.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&PO & Pres. LRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,071.725 Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 12,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001741474-26-000002 · wk-form4_1770154292.xml · derivative · entry 6 Skovronsky Daniel · CIK 0001741474 · EVP, CS&PO & Pres. LRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,684 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 5,641.249 | $1,037.15 | $5,850,821.40 |
DisclosureSEC source: 0001741474-26-000002 · wk-form4_1770154292.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · EVP, CS&PO & Pres. LRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,523.863 Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 12,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001741474-26-000002 · wk-form4_1770154292.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&PO & Pres. LRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,165.112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2025 Filed Nov 10, 2025 23:00 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0001741474-25-000006 · wk-form4_1762815639.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&PO & Pres. LRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,481.112 Read SEC document |
| August 12, 2025 Filed Aug 12, 2025 20:20 UTC | ELI LILLY & Co LLY · Entity 2794 | PurchaseCommon Stock | 1,000 | $634.41 | $634,405.00 |
DisclosureSEC source: 0000059478-25-000214 · wk-form4_1755030049.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,660.112 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $634.21 to $634.42, inclusive. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:04 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 49,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-029971 · wk-form4_1749240252.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,806 F1 · shares: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:15 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 12,684 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000039 · wk-form4_1739394922.xml · derivative · entry 7 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,684 Underlying: Common Stock · 12,684 shares Expires 2026-02-01 F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:15 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 18,771.752 | $868.88 | $16,310,399.88 |
DisclosureSEC source: 0000059478-25-000039 · wk-form4_1739394922.xml · nonDerivative · entry 4 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,660.112 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:15 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 710 | $865.76 | $614,689.60 |
DisclosureSEC source: 0000059478-25-000039 · wk-form4_1739394922.xml · nonDerivative · entry 3 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,888.36 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:15 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 340 | $863.97 | $293,749.80 |
DisclosureSEC source: 0000059478-25-000039 · wk-form4_1739394922.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,598.36 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:15 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 3,950 | $862.69 | $3,407,625.50 |
DisclosureSEC source: 0000059478-25-000039 · wk-form4_1739394922.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,938.36 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 8,989 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000028 · wk-form4_1738704326.xml · derivative · entry 5 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,989 shares Expires 2025-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,003.64 | $811.08 | $3,247,272.33 |
DisclosureSEC source: 0000059478-25-000028 · wk-form4_1738704326.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,888.36 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 8,989 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000028 · wk-form4_1738704326.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 20:16 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 5,724 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000215 · wk-form4_1726172178.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,903 F1 · shares: Among other gift transactions, the reporting person transferred: (a) 2,359 shares of Eli Lilly and Company common stock to DMGCS Family Holdings LLC, which is a single-member limited liability company held and controlled solely by the reporting person's spouse as trustee of a trust for the benefit of the reporting person's spouse and children; and (b) 3,257 shares of Eli Lilly and Company common stock to the reporting person's spouse. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 20:16 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 111 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000215 · wk-form4_1726172178.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,627 Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027520 · wk-form4_1718050526.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,010 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:36 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 8,989 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000052 · wk-form4_1707946554.xml · derivative · entry 3 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,989 Underlying: Common Stock · 8,989 shares Expires 2025-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:36 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 12,910 | $737.26 | $9,518,026.60 |
DisclosureSEC source: 0000059478-24-000052 · wk-form4_1707946554.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,738 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 9,941 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000019 · wk-form4_1706909126.xml · derivative · entry 4 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,941 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,434 | $645.61 | $2,862,634.74 |
DisclosureSEC source: 0000059478-24-000019 · wk-form4_1706909126.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,828 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:25 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 9,941 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000019 · wk-form4_1706909126.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CSO & Pres. LRL & LLY Imm 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 21:19 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 17 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000290 · wk-form4_1699910380.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,321 Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:31 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 249 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000225 · wk-form4_1691785909.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,338 Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,151 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-020713 · wk-form4_1685744248.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,315 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the date of grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:04 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 9,941 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000063 · wf-form4_167641225388328.xml · derivative · entry 3 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,941 Underlying: Common Stock · 9,941 shares Expires 2024-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:04 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 18,388 | $345.12 | $6,346,066.56 |
DisclosureSEC source: 0000059478-23-000063 · wf-form4_167641225388328.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,587 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 15,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000041 · wf-form4_167546169517695.xml · derivative · entry 4 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,675 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 7,035 | $344.15 | $2,421,095.25 |
DisclosureSEC source: 0000059478-23-000041 · wf-form4_167546169517695.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,199 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 15,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000041 · wf-form4_167546169517695.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 21:26 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 17,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-016219 · wf-form4_165429156325887.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,164 F1 · kind: Consists of restricted stock units granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of common stock and vests upon the earlier of (a) the first anniversary of the Date of Grant and (b) the date of the next annual meeting of stockholders following such grant. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:31 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 15,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000052 · wf-form4_164462229151272.xml · derivative · entry 3 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,675 Underlying: Common Stock · 15,675 shares Expires 2023-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:31 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 22,581 | $243.27 | $5,493,279.87 |
DisclosureSEC source: 0000059478-22-000052 · wf-form4_164462229151272.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,559 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:50 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 18,735 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000024 · wf-form4_164392500589775.xml · derivative · entry 4 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,735 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:50 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 8,437 | $245.39 | $2,070,355.43 |
DisclosureSEC source: 0000059478-22-000024 · wf-form4_164392500589775.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,978 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:50 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 18,735 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000024 · wf-form4_164392500589775.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2021 Filed Jun 5, 2021 00:34 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 12,848 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022170 · doc4.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,889 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| April 28, 2021 Filed Feb 3, 2022 21:38 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000020 · wf-form5_164392427358598.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CS&MO & Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,680 F1 · balance_after: The amount reported as directly beneficially owned gives effect to a transfer on April 15, 2021 by the Reporting Person of 70,000 shares to the DMGCS Family Holdings LLC, a single-member limited liability company controlled solely by the Reporting Person until April 28, 2021, on which date 100% of the units and control of the DMGCS Family Holdings LLC were transferred for no consideration to the Reporting Person's spouse as trustee of a trust for the benefit of the Reporting Person's spouse and children as sole beneficiaries. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:44 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 18,735 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000062 · wf-form4_161300786939313.xml · derivative · entry 2 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,735 Underlying: Common Stock · 18,735 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:44 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 18,521 | $205.77 | $3,811,066.17 |
DisclosureSEC source: 0000059478-21-000062 · wf-form4_161300786939313.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,680 Read SEC document |
| December 04, 2020 Filed Dec 7, 2020 23:41 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,889 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032906 · doc4.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,930 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 14:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 25,041 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020191 · doc4.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,041 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests on the anniversary of the date of grant. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:13 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 21,341 | $144.25 | $3,078,439.25 |
DisclosureSEC source: 0000059478-20-000044 · wf-form4_158163562070805.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,159 Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 19:00 UTC | ELI LILLY & Co LLY · Entity 2794 | PurchaseCommon Stock | 5,000 | $108.61 | $543,050.00 |
DisclosureSEC source: 0000059478-19-000285 · wf-form4_157228915675728.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,818 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:39 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 15,619 | $120.17 | $1,876,935.23 |
DisclosureSEC source: 0000059478-19-000063 · wf-form4_154949997417000.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,818 Read SEC document |
| June 14, 2018 Filed Jun 14, 2018 20:08 UTC | ELI LILLY & Co LLY · Entity 2794 | PurchaseCommon Stock | 10,000 | $86.22 | $862,200.00 |
DisclosureSEC source: 0000059478-18-000167 · wf-form4_152900690318505.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,199 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.